Market Trends of Cutaneous T-cell Lymphoma Industry
This section covers the major market trends shaping the Cutaneous T-cell Lymphoma Market according to our research experts:
Mycosis Fungoides Segment is Expected to Register a Significant Growth in the Forecast Years
Mycosis fungoides (MF) is the most frequent type of cutaneous T-cell lymphoma, which usually involves the skin and grows slowly over many years. It is not easy to diagnose, especially in the early stages. MF is more common in men compared to women, in blacks compared to whites, and in the elderly population compared to younger people.
According to the article published by StatPearls in April 2022, Mycosis fungoides had an incidence of around 6 cases per million per year in Europe and the United States. This accounts for 4% of all non-Hodgkin's lymphoma cases. The same source also reported that it is more common in adults over 50 years of age, with a male-to-female ratio of between 1.6 and 2. Additionally, the article further detailed that the disease is more common among blacks than Caucasians or Asians. Thus, the high prevalence of mycosis fungoides is expected to boost segment growth.
Furthermore, regulatory organizations such as the United States Food and Drug Administration and the European Medicines Agency have given special designations to most medications developed for mycosis fungoides. Many of these drugs have been given particular classifications, such as orphan drugs and breakthrough therapy. For instance, in June 2020, Kyowa Kirin, a Japan-based drug maker, launched Poteligeo in Europe. It would be able to treat patients with Sézary syndrome, mycosis fungoides, and rare cancers.
Thus, all the factors mentioned above, such as the rising prevalence of mycosis fungoides and product launches, will boost the segment's growth over the coming years.
North America dominates the Cutaneous T-cell Lymphoma Market
North America dominated the market owing to the increased demand for advanced treatment options and early adoption of new technologies.
According to the American Cancer Society's 2022 statistics, there will be an estimated 80,470 new cases of non-Hodgkins lymphoma and 89,010 cases of lymphoma in 2022 in the United States. Another source from the same organization reported that T-cell lymphomas make up less than 15% of non-Hodgkin's lymphomas in the United States, while cutaneous T-cell lymphomas account for nearly 5% of all lymphomas. Additionally, according to Leukemia & Lymphoma Society 2021, 186,400 people in the United States were diagnosed with leukaemia and lymphoma in 2021. In addition, 825,651 people lived with lymphoma in the United States, 152,671 people lived with Hodgkin lymphoma, and 672,980 people lived with non-Hodgkin lymphoma. Such a high burden of the disease creates the need for treatment and thus propels the growth of the market in the region.
In addition, other companies, such as Amgen and Merck, have been working on developing cancer therapies for T-cell lymphomas. Additionally, in September 2021, Soligenix Inc. reported that the Office of Orphan Products Development of the US FDA had granted orphan drug designation to the active ingredient hypericin for treating T-cell lymphoma, CTCL.
Thus, owing to the abovementioned factors, the North American region is expected to show growth over the forecast period.
